Trials / Completed
CompletedNCT04522297
Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome
Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Acute Kidney Injury
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- National Hepatology & Tropical Medicine Research Institute · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Hepatorenal syndrome is a functional renal impairment occurring in cirrhotic patients . It develops secondary to splanchnic arterial vasodilatation which decreases the effective blood volume, activate the renin-angiotensin-aldosterone system, and stimulate of sympathetic nervous system.This study aims to compare the efficacy of nor-epinephrine versus midodrine/ octreotide, together with intravenous albumin on renal functions of patients with hepatorenal acute kidney injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Midodrine/Octreotide | oral midodrine plus octreotide as subcutaneous injection |
| DRUG | Nor-epinephrine | Intravenous infusion norepinephrine |
Timeline
- Start date
- 2018-04-15
- Primary completion
- 2020-01-23
- Completion
- 2020-01-23
- First posted
- 2020-08-21
- Last updated
- 2020-08-21
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04522297. Inclusion in this directory is not an endorsement.